Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals

  • Founded: 2014
  • Location: Cambridge, MA
  • Employee range: 1 - 10
  • Clinical stage: Clin1b
  • Therapy area: Ischemic stroke
  • Drug types: NEU, X_X, CVV, PN
  • Lead product: AST-004
  • Product link: https://www.astrocytepharma.com/portfolio/
  • Funding: $6M B Aug 2023
  • Investors: Dreavent Capital, Alzheimer's Drug Discovery Foundation


astrocytepharma.com

linkedin.com


Short description:

Treatment of TBI, Stroke, and Alzheimer’s Disease, and other injuries to the brain

Drug notes:

Also Clin1 TBI, Clin0 concussion, RD/Clin0 Alzheimer's; AST-008 RD/Clin0 pain, migraine; undisclosed RD/Clin0 CNS conditions

Long description:

Astrocyte Pharmaceuticals uses astrocytes to develop neuroprotective therapies for treatment of traumatic brain injuries, concussions, stroke, and neurodegenerative disease. Astrocytes and other glial cells play vital functions in brain cell maintenance and repair, making them great therapeutic targets. Astrocyte Pharma is a clinical-stage biopharma company. Co-founders William S. Korinek and James D. Lechleiter started Astrocyte Pharma in 2014.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com